


CONTACT INFORMATION

convEyXO

Frédéric Tonglet

+32 496 38 09 64

Frederic.tonglet@conveyxo.com



CONVEYXO

RELEASE EXOSOMES FULL POTENTIAL

RELEASE DATE

26/05/2023 09:00 AM CET+1

convEyXO and SomesTech Announce XomeXBio Joint Venture to Unleash Full Potential of Targeted Exosomes as drug delivery system for precision medicine

The collaboration includes the development, commercialization and supply of a breakthrough platform based on SomesTech nanoengineering technology strengthened and validated by convEyXO to enable loading of exosomes capable to delivering bioactive compounds in a targeted way.

Gosselies, May 26, 2023,

convEyXO, a biopharmaceutical company committed to making exosomes-based therapies more widely available and affordable with their breakthrough large scale and high yield manufacturing technology

And

SomesTech, a company committed to discover and develop innovative engineered exosomes combined with their breakthrough nanoengineering technology,

Today announce a collaboration through their joint venture XomeXBio. The goal of the JV is to advance the development, regulatory approval and commercialization of nanoengineering technology enabling new paths to address unmet medical needs and overcome challenging healthcare issues.

Exosomes are tiny vesicles that ferry biomolecules like proteins and nucleic acids between cells. With properties inherited from their source cells, these versatile vesicles offer a safer, lower-cost, and higher-quality alternative to regenerative stem cell therapies. Thanks to SomesTech nanoengineering technology, they can be enriched with compounds of interest, holding great promise as a new method for drug delivery. Exosomes secreted from mesenchymal stem cells retain the immunomodulatory and anti-inflammatory properties of their source cells and present a promising alternative to cell therapies in regenerative medicine, but potential applications of exosomes are many, as the vesicles can be loaded with

ConvEyXO SA

Brussels South Charleroi BioPark, Rue Auguste Piccard 48

B-6041 Charleroi

VAT BE0725.874.259

molecules that amplify or change their activity, such as RNA, proteins, or any water-soluble drug compound.

This JV sees the emergence of a major international player in the field of instrumentation for loaded exosomes drug based therapies. The partnership will initially focus on aligning the two companies' efforts to advance SomesTech's technology. Developments will focus on both the ability to load exosomes with drugs on a large scale and the validation of the instrumentation to pharmaceutical standards.

These developments will benefit from convEyXO's expertise in the pharmaceutical field as well as in the technological and biological activity validation of loaded exosomes for therapeutic purposes. First therapeutic applications envisaged are in the field of musculoskeletal diseases and in oncology.

“This collaboration between convEyXO and SomesTech further expands respective breakthrough micro-fluidic based technology platform in exosomes and provides a clear illustration of the international scope of both companies”, said Jean-Paul Prieels, Founder and CEO of convEyXO.

“We selected SomesTech as our partner given their unique expertise in micro-fluidic translated into a nano-engineering technology for exosomes loading. A robust and scalable method to enrich the vesicles with (water-soluble) molecules of interest, without altering their inherent properties, is invaluable to a bright future for therapeutic exosomes. “, said Frédéric Tonglet, Deputy CEO of convEyXO.

“The joint venture and partnership with convEyXO will provide a significant international route to market for SomesTech technology. SomesTech will leverage convEyXO pharmaceutical expertise and GMP know-how to enhance our technology and accelerate the international development of loaded exosomes based therapies”, said Hui Yang, Founder and CEO of SomesTech.

About convEyXO

ConvEyXO strives to unleash the full therapeutic potential of exosomes. The company was founded in 2019 by a team of seasoned cell therapy experts committed to making exosome-based therapies more widely available and affordable. Through strategic partnerships, ConvEyXO is leading the way in developing technologies to unlock the full therapeutic potential of exosomes at an affordable cost.

Additional information is available at <https://www.conveyxo.com>

About SomesTech

Through the complementary application of biological insights and technological advancements, SomesTech is committed to discover and develop innovative engineered exosomes combined with breakthrough nanotechnology, enabling new paths to address unmet medical needs and overcome challenging healthcare issues.

Additional information is available at <http://www.somestech.com/>

ConvEyXO SA


Brussels South Charleroi BioPark, Rue Auguste Piccard 48
B-6041 Charleroi
VAT BE0725.874.259

Contact for convEyXO:

Frédéric Tonglet

+32 496 38 09 64

frederic.tonglet@conveyxo.com



ConvEyXO SA

Brussels South Charleroi BioPark, Rue Auguste Piccard 48

B-6041 Charleroi

VAT BE0725.874.259